CA2914049C - Pharmaceutical formulations of a hif hydroxylase inhibitor - Google Patents

Pharmaceutical formulations of a hif hydroxylase inhibitor Download PDF

Info

Publication number
CA2914049C
CA2914049C CA2914049A CA2914049A CA2914049C CA 2914049 C CA2914049 C CA 2914049C CA 2914049 A CA2914049 A CA 2914049A CA 2914049 A CA2914049 A CA 2914049A CA 2914049 C CA2914049 C CA 2914049C
Authority
CA
Canada
Prior art keywords
red
iron oxide
capsule
titanium dioxide
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2914049A
Other languages
English (en)
French (fr)
Other versions
CA2914049A1 (en
Inventor
David CONCA
Lee Allen Flippin
Scott David Leigh
Claudia WITSCHI
Lee Robert Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2914049(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of CA2914049A1 publication Critical patent/CA2914049A1/en
Application granted granted Critical
Publication of CA2914049C publication Critical patent/CA2914049C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2914049A 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor Active CA2914049C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
US61/831,909 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (2)

Publication Number Publication Date
CA2914049A1 CA2914049A1 (en) 2014-12-11
CA2914049C true CA2914049C (en) 2021-10-12

Family

ID=51063834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2914049A Active CA2914049C (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Country Status (24)

Country Link
US (3) US20160120859A1 (enExample)
EP (2) EP3003284B1 (enExample)
JP (4) JP6604941B2 (enExample)
KR (3) KR102291860B1 (enExample)
CN (5) CN105377242A (enExample)
AU (1) AU2014274890B2 (enExample)
CA (1) CA2914049C (enExample)
CY (1) CY1122951T1 (enExample)
DK (1) DK3003284T3 (enExample)
ES (1) ES2786924T3 (enExample)
HR (1) HRP20200615T1 (enExample)
HU (1) HUE049623T2 (enExample)
IL (3) IL296484B2 (enExample)
LT (1) LT3003284T (enExample)
ME (1) ME03777B (enExample)
MX (3) MX2015016536A (enExample)
PL (1) PL3003284T3 (enExample)
PT (1) PT3003284T (enExample)
RS (1) RS60464B1 (enExample)
SG (1) SG11201509764RA (enExample)
SI (1) SI3003284T1 (enExample)
SM (1) SMT202000190T1 (enExample)
WO (1) WO2014197660A1 (enExample)
ZA (1) ZA201508712B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3470397B1 (en) 2012-07-16 2021-12-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
ES2898878T3 (es) 2017-09-04 2022-03-09 Sandoz Ag Cocristal de un inhibidor de la prolil·hidroxilasa de HIF disponible por vía oral
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
WO2023140901A1 (en) * 2022-01-21 2023-07-27 Elanco Us Inc. Molidustat formulations and methods of use for treatment of anemia in cats
CN116832005A (zh) * 2022-03-23 2023-10-03 石药集团中奇制药技术（石家庄）有限公司 一种罗沙司他胶囊
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) * 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat
WO2025111214A1 (en) 2023-11-22 2025-05-30 Fibrogen, Inc. [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)
CN118436652A (zh) * 2024-04-18 2024-08-06 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种罗沙司他药物制剂及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
HU229475B1 (en) 2001-12-06 2014-01-28 Fibrogen Methods of increasing endogenous erythropoietin (epo)
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
US20060018959A1 (en) 2002-12-16 2006-01-26 Kissei Pharmaceutical Co. Ltd. Solid drug for oral use
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
WO2005087237A1 (ja) * 2004-03-16 2005-09-22 Asahi Kasei Pharma Corporation ファスジル含有製剤及びその安定性を改善する方法
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
EP1944029B1 (en) 2005-10-31 2011-12-21 Kowa Company, Ltd. Pharmaceutical preparation having excellent photostability
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CN102351791B (zh) 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
JP2009526047A (ja) * 2006-02-09 2009-07-16 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムの安定な医薬製剤
US20070259960A1 (en) 2006-02-16 2007-11-08 Fibrogen, Inc. Compounds and methods for treatment of stroke
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
KR20100099113A (ko) 2007-10-12 2010-09-10 아스트라제네카 아베 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
WO2009058403A1 (en) 2007-11-02 2009-05-07 Fibrogen, Inc. Methods for reducing blood pressure
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20110039885A1 (en) 2007-12-06 2011-02-17 Fibrogen, Inc. Methods for increasing endothelial progenitor cells
EP2231156A1 (en) 2007-12-07 2010-09-29 Fibrogen, Inc. Methods for increasing white blood cells
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
CN102264740B (zh) 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
WO2010087462A1 (ja) 2009-01-29 2010-08-05 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
WO2012097329A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing mean corpuscular volume
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
CA2842730C (en) 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
EP3470397B1 (en) 2012-07-16 2021-12-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SG10202009266PA (en) 2013-01-24 2020-10-29 Fibrogen Inc Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor

Also Published As

Publication number Publication date
RU2015151056A3 (enExample) 2018-05-03
RS60464B1 (sr) 2020-07-31
AU2014274890B2 (en) 2019-10-03
LT3003284T (lt) 2020-04-27
IL242759B1 (en) 2023-01-01
IL296484B1 (en) 2024-11-01
CY1122951T1 (el) 2021-10-29
US10765672B2 (en) 2020-09-08
IL242759A (enExample) 2015-12-31
IL242759B2 (en) 2023-05-01
JP2023068197A (ja) 2023-05-16
RU2681304C2 (ru) 2019-03-06
ME03777B (me) 2021-04-20
IL296484B2 (en) 2025-03-01
JP6604941B2 (ja) 2019-11-13
US20190008846A1 (en) 2019-01-10
SMT202000190T1 (it) 2020-05-08
PT3003284T (pt) 2020-08-10
JP6861758B2 (ja) 2021-04-21
ZA201508712B (en) 2020-07-29
ES2786924T3 (es) 2020-10-14
HUE049623T2 (hu) 2020-09-28
BR112015029693A2 (pt) 2017-07-25
RU2015151056A (ru) 2017-07-14
CN111728950A (zh) 2020-10-02
CN111728952A (zh) 2020-10-02
MX2020003096A (es) 2020-08-17
DK3003284T3 (da) 2020-03-30
IL296484A (en) 2022-11-01
BR112015029693A8 (pt) 2019-12-24
KR102291860B1 (ko) 2021-08-20
WO2014197660A1 (en) 2014-12-11
JP2019137703A (ja) 2019-08-22
SG11201509764RA (en) 2015-12-30
KR20160018514A (ko) 2016-02-17
KR20210104173A (ko) 2021-08-24
CA2914049A1 (en) 2014-12-11
SI3003284T1 (sl) 2020-08-31
AU2014274890A1 (en) 2015-12-17
CN111728951A (zh) 2020-10-02
IL298998A (en) 2023-02-01
US20160120859A1 (en) 2016-05-05
EP3708154A1 (en) 2020-09-16
IL298998B2 (en) 2024-07-01
JP2021100971A (ja) 2021-07-08
JP2016523846A (ja) 2016-08-12
NZ714554A (en) 2021-06-25
US20220054474A1 (en) 2022-02-24
HK1222550A1 (en) 2017-07-07
HRP20200615T1 (hr) 2020-07-10
MX2015016536A (es) 2016-08-11
PL3003284T3 (pl) 2020-08-10
EP3003284A1 (en) 2016-04-13
CN110448537A (zh) 2019-11-15
IL298998B1 (en) 2024-03-01
NZ754196A (en) 2021-06-25
CN105377242A (zh) 2016-03-02
EP3003284B1 (en) 2020-02-12
MX2022011225A (es) 2022-10-07
KR20220164069A (ko) 2022-12-12

Similar Documents

Publication Publication Date Title
US10765672B2 (en) Pharmaceutical formulations of a HIF hydroxylase inhibitor
CA2916033A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
CN108938626B (zh) 一种稳定性好和安全性高的卡络磺钠药物组合物及其制备方法和应用
CN118806764A (zh) 缓释制剂及其使用方法
CN102365284A (zh) 治疗2型糖尿病的药物组合物
JP5713990B2 (ja) ２型糖尿病治療用の医薬組成物
NZ754196B2 (en) Pharmaceutical formulations of a HIF hydroxylase inhibitor
HK40032448A (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
HK1222550B (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
NZ714554B2 (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
BR112015029693B1 (pt) Comprimido e cápsula compreendendo ácido [(4-hidróxi-1-metil-7-fenóxi-isoquinolina-3-carbonil)-amino]-acético
TWI462925B (zh) 治療２型糖尿病的藥物組合物
HK1147699A (en) Pharmaceutical composition for the treatment of type 2 diabetes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190513

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20260319

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20260319

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260514

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260520

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260715

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260715